Distribution of serum MBL levels in diabetic patients with diabetic nephropathy (DN) and with persistent normoalbuminuria and normal controls.

<p>All data are medians and in-terquartile ranges (IQR). <i>P</i> values refer to Mann-Whitney <i>U</i> tests for differences between groups.</p

Correlation between the serum MBL levels and other factors (a) Correlation between the serum MBL levels and HbA1c; (b) Correlation between the serum MBL levels and Hs-CRP.

<p>Correlation between the serum MBL levels and other factors (a) Correlation between the serum MBL levels and HbA1c; (b) Correlation between the serum MBL levels and Hs-CRP.</p

sj-docx-1-jic-10.1177_08850666241228841 - Supplemental material for Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study

Supplemental material, sj-docx-1-jic-10.1177_08850666241228841 for Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study by Xiaohua Chen, Ying Zhu, Leer Shen, Dan Zhou, Nannan Feng and Qiang Tong in Journal of Intensive Care Medicine</p

Silencing of SATB1 expression by different liposomes.

<p>(<b>A</b>) Fluorescent imaging of MKN-28 cells transfected by TSCL-shSATB1 and TSMCL-shSATB1. (<b>B</b>) Quantitative analysis of transfection efficiency of TSCL-shSATB1 and TSMCL-shSATB1 by FACS. (<b>C</b>) Western blot analysis of SATB1 protein level in MKN-28 cells transfected by TSCL-shSATB1 and TSMCL-shSATB1. (<b>D</b>) Real-time PCR analysis of SATB1 mRNA level in MKN-28 cells transfected by TSCL-shSATB1 and TSMCL-shSATB1. The values were expressed as mean±SD from three independent experiments. * p<0.05 compared with mock control; # p<0.05 compared with TSCL-shSATB1.</p

Particle size, polydispersity and zeta potential of liposomes.

<p>The data were expressed as mean±SD (n = 3).</p><p># p <0.05 TSCL-shSATB1 vs. TSCL,TSCL-DOX-shSATB1 vs. TSCL-DOX, TSMCL-shSATB1 vs. TSMCL,TSMCL-DOX-shSATB1 vs. TSMCL-DOX,</p><p>*p <0.05 TSMCL vs. TSCL, TSMCL-DOX vs. TSCL-DOX, TSMCL-shSATB1 vs. TSCL-shSATB1 and TSMCL-DOX-shSATB1 vs. TSCL-DOX-shSATB1.</p

In vitro anti-tumor effects of different liposomes to MKN-28 cells.

<p>(<b>A</b>) The viability of cells after treatment with liposomes loaded with different concentrations of DOX. (<b>B</b>) The viability of cells after treatment with liposomes loaded with different concentrations of shSATB1. (<b>C</b>) The viability of cells after treatment with liposomes as indicated. The values were expressed as mean±SD (n = 3). (<b>D</b>) The apoptosis of cells after treatment with liposomes as indicated.</p

DOX release from different liposomes.

<p>The release of DOX from different liposomes at 37°C (<b>A</b>) and 42°C (<b>B</b>) after incubation with PBS or 50% FBS. The values were expressed as mean±SD (n = 3).</p

Uptake of DOX and FAM-labeled siRNA by MKN-28 cells.

<p>(<b>A</b>) Imaging of cells after treatment with TSCL-siRNA and TSMCL-siRNA. (<b>B</b>) Imaging of cells after treatment with TSCL-DOX and TSMCL-DOX. (<b>C</b>) Imaging of cells after treatment with TSCL-DOX-siRNA and TSMCL-DOX-siRNA. (<b>D</b>) Typical detailed imaging of the location of DOX and siRNA in cells after treatment with TSMCL-DOX-siRNA.</p

In vivo anti-tumor activity of different liposomes.

<p>(<b>A</b>) Typical imaging of xenografted tumor. (<b>B</b>) Tumor size after treatment with Free DOX, TSMCL-DOX, TSMCL-shSATB1, TSCL-DOX-shSATB1, or TSMCL- DOX-shSATB1, treatment with normal saline was used as control. Data were presented as mean±SD (n = 6). (<b>C</b>) Survival curves of tumor bearing mice treated with Free DOX, TSMCL-DOX, TSMCL-shSATB1, TSCL-DOX-shSATB1, or TSMCL- DOX-shSATB1, treatment with normal saline was used as control.</p

Baseline characteristics of patients experiencing short-term adverse events.

<p>CRP = C-reactive protein. ESR = erythrocyte sedimentation rate. Axial phenotype is ankylosing spondylitis which initially predominantly affects the spine and pelvic joints.</p><p>Baseline characteristics of patients experiencing short-term adverse events.</p